Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart (R) Injector: Results of the Prospective Cohort Study REBIFLECT

Rieckmann P, Ziemssen T, Penner IK, Raji A, Wagner T, Richter J, Zettl UK (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Advances in Therapy Springer Verlag (Germany)

DOI: 10.1007/s12325-022-02100-w

Abstract

Introduction: Consistent treatment adherence is an important determinant of durable response in multiple sclerosis (MS). Published data indicate that adherence to > 80% of prescribed doses may be considered optimal. Feedback of electronic application monitoring data to patients has been considered a promising means to support high adherence.

Involved external institutions

Technische Universität Dresden DE Germany (DE) Heinrich-Heine-Universität Düsseldorf DE Germany (DE) Merck KGaA DE Germany (DE) Universität Rostock DE Germany (DE) Medical Park AG DE Germany (DE)

How to cite

APA:

Rieckmann, P., Ziemssen, T., Penner, I.-K., Raji, A., Wagner, T., Richter, J., & Zettl, U.K. (2022). Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart (R) Injector: Results of the Prospective Cohort Study REBIFLECT. Advances in Therapy. https://doi.org/10.1007/s12325-022-02100-w

MLA:

Rieckmann, Peter, et al. "Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart (R) Injector: Results of the Prospective Cohort Study REBIFLECT." Advances in Therapy (2022).

BibTeX: Download